Chronic lymphocytic leukaemia (CLL) is the most commonly diagnosed leukaemia in the Western world, with an average age of diagnosis being over 65 years 1, 2. Despite development of new targeted therapeutics; emerging resistance, pharmacoeconomic sustainability and side-effect intolerability remain significant barriers to patient care and potential disease curability
• α,β unsaturated ketone was observed as an effective nitrovinyl substitute for ethanoanthracene lead compounds, reaching low micromolar IC 50 values across both CLL cell lines (at least x10 as potent as fludarabine)
• NCI 60 cell line COMPARE analysis of most promising compounds suggests potential effect on cellular redox mechanisms/biochemical pathways; while confirming broad anticancer activity. Haematological malignancies responded the most to treatment.
• Two lead compounds JM 07 and CC-38 (representing nitrovinyl and chalcone based drug classes respectively) displayed a probable ROS dependant effect on cell viability when co-treated with antioxidants N-acetyl cysteine or Trolox 
